Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.
Actively Recruiting
Researchers are investigating the real-world use of encorafenib plus binimetinib for patients with unresectable advanced or metastatic melanoma that has a BRAF V600 mutation. This observational study focuses on documenting treatment effects, quality of life, safety, and tolerability after these drugs became commercially available in Germany, Austria, and Switzerland. The study specifically looks at patients treated in the first and second line settings after prior checkpoint inhibitor therapy. The study observes patients who are treated with encorafenib plus binimetinib according to the approved product guidelines. Participants may have started this treatment up to six months before joining the study or may begin treatment soon after enrollment. The study tracks treatment details, effectiveness, side effects, and patient-reported outcomes over a median treatment duration of about 12 months, with a total observation period of up to 90 months. Participants will be followed through regular documentation of their disease and treatment progress, including patient and disease profiles, treatment sequences, adverse events, and quality of life assessments using questionnaires. The main outcome measured is progression-free survival at 12 months after treatment start. Researchers will also evaluate treatment duration, interruptions, dose intensity, and physician satisfaction. Long-term safety and prognostic factors will be monitored throughout the observation period until study completion in September 2027.
Actively Recruiting
Researchers are studying metastatic colorectal carcinoma mCRC patients who have a specific BRAFV600E mutation, which is linked to poorer outcomes compared to those without it. This mutation leads to shorter survival times after initial treatments, prompting the need for new therapy combinations. This research aims to observe how the drugs encorafenib and cetuximab work together in real-world settings for patients who have already received prior systemic therapies. This non-interventional, prospective, longitudinal study focuses on patients treated with encorafenib plus cetuximab following prior systemic therapy. The study collects data on treatment effectiveness, safety, and quality of life among a broader patient population in Germany, Austria, and Switzerland. Patients may have started treatment up to three months before joining the study or plan to start soon, and the study observes their outcomes without influencing treatment decisions. Participants will be monitored through data collection on their disease and treatment profiles, including patient and physician assessments, adverse events, and treatment details. The main outcome measured is overall survival at 12 months after starting treatment. Additional information gathered includes treatment duration, dose intensity, interruptions, and patient-reported quality of life using questionnaires. Safety and tolerability are also evaluated throughout treatment, with follow-up averaging nine months.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and quality of life for combining Abemaciclib with either an Aromatase Inhibitor or Fulvestrant in women with metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase IV trial focuses on both pre- and postmenopausal patients receiving first-line treatment. A digital health app called CANKADO will be used to track side effects and patient-reported outcomes daily, alongside standard documentation. The study also aims to explore biomarkers to better understand treatment responses and resistance. Participants will receive either Abemaciclib combined with an Aromatase Inhibitor Anastrozole, Letrozole, or Exemestane taken orally twice daily plus daily Aromatase Inhibitor tablets every 24 hours in 28-day cycles, or Abemaciclib with Fulvestrant which is given as an injection on specific days within 28-day cycles. The two treatment groups are experimental and non-randomized, with no masking. The trial includes monitoring for side effects and quality of life throughout treatment. During the study, participants will regularly report side effects and global health status using questionnaires at multiple time points up to 24 months, including specialized breast cancer quality of life modules. Researchers will assess progression-free survival up to 48 months, as well as adverse events, hospitalizations, clinical benefit rate, overall survival, and tumor response. The use of the CANKADO app for side effect reporting is strongly recommended but not mandatory. Participants will be followed for safety and outcomes throughout the trial duration.
Actively Recruiting
Researchers are evaluating how well Fruquintinib works to treat adults with metastatic colorectal cancer who have already received standard treatments. This observational study in Germany aims to analyze patient response to Fruquintinib in routine clinical practice, focusing on survival, safety, medical care usage, and quality of life. The study also includes a translational research project to link clinical data with biomarkers for better understanding treatment benefit. Participants receive Fruquintinib as determined by their treating physician according to approved guidelines. The study collects real-world data from about 150 patients across various healthcare settings. Archival tumor tissue and blood samples are gathered to study biomarkers and circulating tumor DNA, which may indicate treatment response. During the study, participants health and treatment effects are monitored through clinical data and biomarker analysis. Researchers measure disease control, response rates, survival, adverse events, quality of life, treatment duration, hospitalizations, and other outcomes up to 33 months. The study provides insight into Fruquintinibs use and impact in everyday care over an average of 6 to 7 months of treatment and extended follow-up.
Actively Recruiting
Researchers are conducting a large, multi-country observational study called LIVER-R to collect real-world data on patients with hepatobiliary cancers, including unresectable hepatocellular carcinoma uHCC, advanced biliary tract cancer aBTC, and other related liver cancers. The study aims to evaluate the effectiveness of treatment regimens that include durvalumab-based therapies or other approaches used in routine clinical practice or early access programs. The study is descriptive and will analyze survival as well as other important clinical outcomes over time. Participants will be observed during their regular clinical care, with data collected both prospectively during visits and retrospectively from medical records, covering a baseline period of up to 5 years before treatment initiation. The study groups include patients receiving durvalumab-based regimens alone or in combination with local regional therapy LRT, as well as those treated with non-durvalumab therapies. Follow-up will continue for at least 2 years or until death, loss to follow-up, withdrawal, or study end. Throughout the study, researchers will gather information on survival rates, treatment duration, progression, recurrence, liver function, treatment patterns, adverse events requiring medical intervention, and patient and provider characteristics. Data will be collected at enrollment and every six months, with real-world overall survival as the primary measure. This extensive monitoring aims to provide a comprehensive view of treatment outcomes and patient experiences in real-world settings across multiple hepatobiliary cancer types.